Loading…
Employees: 957
Size i-SENS (099190.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $268M, the 489th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩12,310 on 6 Nov 2026.
Performance Over six months the shares fell 41.9%, against -8.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +5.3%); the operating margin is 4.0% (peer median 4.9%).
Valuation It trades at 31.6× forward earnings against a peer median of 15.5× (2nd most expensive of 10).
Capital Return on invested capital runs 2.6 points below its cost of capital (5.5% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩334B | ₩315B | ₩291B | ₩265B | ₩265B |
| Revenue growth | — | +8% | +10% | 0% | — |
| Gross profit | n/a | ₩119B | ₩107B | ₩101B | ₩101B |
| EBITDA | n/a | ₩24.6B | ₩17.6B | ₩23.5B | ₩31.2B |
| Net income | -₩7.63B | -₩5.15B | -₩1.79B | ₩3.71B | ₩16.1B |
| Free cash flow | n/a | -₩7.60B | ₩7.78B | -₩29.0B | -₩15.3B |
| Capital expenditure | n/a | ₩32.1B | ₩15.6B | ₩44.2B | ₩26.0B |
| Total debt | n/a | ₩174B | ₩174B | ₩144B | ₩101B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 099190.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.3% | -5.6% | 2nd lowest of 21 |
| 6-month return | -41.9% | -8.2% | 2nd lowest of 21 |
| Distance from 52-week high | -55.4% | -30.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +6.7% | +5.3% | 11th highest of 21 |
| Operating margin | 4.0% | 4.9% | 10th lowest of 21 |
| Forward P/E | 31.6× | 15.5× | 2nd most expensive of 10 |
| ROIC minus cost of capital | -2.6 pp | -3.9 pp | 8th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| i-SENS 099190.KS | South Korea | $268M | -42% | +7% | 4% | 31.6× | n/a | n/a |
| i3system 214430.KS | South Korea | $287M | -48% | +8% | 13% | n/a | n/a | n/a |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | n/a | 26.0% | -11.9% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 10.7× | -9.0% | +20.2% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |